ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO

ASRS ’23: Missed Injections for AMD/DME/RVO and Anatomic Response to Vabysmo in Wet AMDПодробнее

AsclepiX Therapeutics - Innovation Showcase at Ophthalmology Innovation Summit @ ASRS 2019Подробнее

Allegro Ophthalmics: First-in-Class Anti-Integrin Agent (OIS@ASRS 2016)Подробнее

ASRS 2021: The Pipeline for Wet AMD and GAПодробнее

Part 2: Long-term Outcomes in the Treatment of Wet AMDПодробнее

AsclepiX Therapeutics Corporate VideoПодробнее

New Therapies Wet AMD Could Improve Outcomes for Patients | ASRSПодробнее

ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMDПодробнее

ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMDПодробнее

Real World Retina: PhiladelphiaПодробнее

Changes in vision due to Dry AMDПодробнее

Wet AMDПодробнее

Carl Awh, MD on the Reintroduction of #Susvimo for Wet #AMD After a Voluntary Recall #ASRS #retinaПодробнее

Symptoms of Macular DegenerationПодробнее

ASRS 2019 STREET TEAM Raj K Maturi, MDПодробнее

Brolucizumab demonstrates drying effect in patients with DMEПодробнее

ASRS 2019 Street Team: Peter K. Kaiser, MDПодробнее

This is what Macular Degeneration does to your visionПодробнее